CriticalSorb: a novel efficient nasal delivery system for human growth hormone based on Solutol HS15.
The absorption enhancing efficiency of CriticalSorb for human growth hormone (MW 22 kDa) was investigated in the conscious rat model. The principle absorption enhancing component of CriticalSorb, Solutol HS15, comprises polyglycol mono- and di-esters of 12-hydroxystearic acid combined with free polyethylene glycol. When administering hGH nasally in rats with increasing concentrations of Solutol HS15, it was found that for a 10%w/v solution formulation a bioavailability of 49% was obtained in the first 2h after administration. Furthermore it was shown that the most effective ratio of Solutol HS15 to hGH was 4:1 on a mg to mg basis. Histopathology studies in rats after 5 days repeated nasal administration showed that Solutol HS15 had no toxic effect on the nasal mucosa. These results have been confirmed in a 6 month repeat nasal toxicity study in rats. It can be concluded that the principle absorption enhancing component of CriticalSorb - Solutol HS15 - is a potent and non- toxic nasal absorption enhancer that warrants further development.
Critical Pharmaceuticals Ltd., BioCity, Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK.
Lisbeth
L
Illum
Faron
F
Jordan
Andrew L
AL
Lewis
D000281:Administration, Intranasal; D000818:Animals; D001682:Biological Availability; D019382:Human Growth Hormone / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D009297:Nasal Mucosa / Q000378:metabolism*; D014677:Pharmaceutical Vehicles / Q000378:metabolism*; D011092:Polyethylene Glycols / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013229:Stearic Acids / Q000378:metabolism*
D014677:Pharmaceutical Vehicles; D013229:Stearic Acids; D019382:Human Growth Hormone; D011092:Polyethylene Glycols; C067028:Solutol HS 15